Crit Care Med:哌拉西林-他唑巴坦血浆浓度测量的意义

2017-02-28 MedSci MedSci原创

肥胖和一些危重疾病影响抗生素的药代动力学,但哌拉西林-他唑巴坦连续静脉滴注的药物动力学在肥胖及危重病人中的研究很少。近期,一项发表在杂志Crit Care Med上的研究旨在比较哌拉西林在严重肥胖和非肥胖患者发生严重脓毒症或败血症休克时的药代动力学。此项研究是前瞻性对照研究。研究者们使用16g-2g / 24小时连续静脉滴注哌拉西林-他唑巴坦治疗危重性严重肥胖(体重指数> 35kg / m)

肥胖和一些危重疾病影响抗生素的药代动力学,但哌拉西林-他唑巴坦连续静脉滴注的药物动力学在肥胖及危重病人中的研究很少。


近期,一项发表在杂志Crit Care Med上的研究旨在比较哌拉西林在严重肥胖和非肥胖患者发生严重脓毒症或败血症休克时的药代动力学。

此项研究是前瞻性对照研究。研究者们使用16g-2g / 24小时连续静脉滴注哌拉西林-他唑巴坦治疗危重性严重肥胖(体重指数> 35kg / m)和非肥胖患者(体重指数<30kg / m)。通过高压液相色谱在7天时间内每12小时测量哌拉西林的血浆浓度。在两组之间比较未结合的哌拉西林血浆浓度和浓度超过64mg / L(铜绿假单胞菌的最小抑制浓度的4倍)的血浆浓度的分数时间。

此项研究共招募了11名严重肥胖和12名非肥胖患者,并获得294个血液样本。没有观察到哌拉西林血浆浓度在组间随时间的统计学显着差异。超过64 mg / L的分数时间分别为:肥胖患者64%(43-82%),非肥胖患者93%(85-100%),p = 0.027,具有组内和组间变异性。五个非肥胖患者和两个肥胖患者经历了哌拉西林血浆浓度的潜在毒性。

当靶向64mg / L时,蒙特卡罗模拟显示12g-1.5g / 24小时在两组中都不足,而16g-2g / 24小时仅在非肥胖患者中是足够。

此项研究表明:使用常规剂量的16g-2g / 24小时连续输注,当面对最小抑制浓度较高的病原体时,肥胖患者比非肥胖患者更可能面临哌拉西林剂量的不足。对于高危患者的哌拉西林药物血浆浓度的检测是有必要的,这可以及时提示他们是否药物使用过量、发生药物毒性以及剂量不足和治疗失败。

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2069575, encodeId=476f20695e5ef, content=<a href='/topic/show?id=e4063990198' target=_blank style='color:#2F92EE;'>#哌拉西林-他唑巴坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39901, encryptionId=e4063990198, topicName=哌拉西林-他唑巴坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Dec 16 09:28:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544439, encodeId=96181544439e7, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607274, encodeId=4f49160e274d1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178285, encodeId=2d9a1e828537, content=这个可以Meta一下吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Wed Mar 01 06:45:21 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178277, encodeId=17191e8277d5, content=stop, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Wed Mar 01 06:14:05 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178255, encodeId=ff911e825564, content=很好的学习资料,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161026/IMG58107C0F82E499574.jpg, createdBy=00e81970035, createdName=1e15b6fem30(暂无匿称), createdTime=Tue Feb 28 23:44:01 CST 2017, time=2017-02-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2069575, encodeId=476f20695e5ef, content=<a href='/topic/show?id=e4063990198' target=_blank style='color:#2F92EE;'>#哌拉西林-他唑巴坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39901, encryptionId=e4063990198, topicName=哌拉西林-他唑巴坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Dec 16 09:28:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544439, encodeId=96181544439e7, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607274, encodeId=4f49160e274d1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178285, encodeId=2d9a1e828537, content=这个可以Meta一下吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Wed Mar 01 06:45:21 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178277, encodeId=17191e8277d5, content=stop, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Wed Mar 01 06:14:05 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178255, encodeId=ff911e825564, content=很好的学习资料,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161026/IMG58107C0F82E499574.jpg, createdBy=00e81970035, createdName=1e15b6fem30(暂无匿称), createdTime=Tue Feb 28 23:44:01 CST 2017, time=2017-02-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2069575, encodeId=476f20695e5ef, content=<a href='/topic/show?id=e4063990198' target=_blank style='color:#2F92EE;'>#哌拉西林-他唑巴坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39901, encryptionId=e4063990198, topicName=哌拉西林-他唑巴坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Dec 16 09:28:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544439, encodeId=96181544439e7, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607274, encodeId=4f49160e274d1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178285, encodeId=2d9a1e828537, content=这个可以Meta一下吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Wed Mar 01 06:45:21 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178277, encodeId=17191e8277d5, content=stop, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Wed Mar 01 06:14:05 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178255, encodeId=ff911e825564, content=很好的学习资料,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161026/IMG58107C0F82E499574.jpg, createdBy=00e81970035, createdName=1e15b6fem30(暂无匿称), createdTime=Tue Feb 28 23:44:01 CST 2017, time=2017-02-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2069575, encodeId=476f20695e5ef, content=<a href='/topic/show?id=e4063990198' target=_blank style='color:#2F92EE;'>#哌拉西林-他唑巴坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39901, encryptionId=e4063990198, topicName=哌拉西林-他唑巴坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Dec 16 09:28:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544439, encodeId=96181544439e7, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607274, encodeId=4f49160e274d1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178285, encodeId=2d9a1e828537, content=这个可以Meta一下吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Wed Mar 01 06:45:21 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178277, encodeId=17191e8277d5, content=stop, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Wed Mar 01 06:14:05 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178255, encodeId=ff911e825564, content=很好的学习资料,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161026/IMG58107C0F82E499574.jpg, createdBy=00e81970035, createdName=1e15b6fem30(暂无匿称), createdTime=Tue Feb 28 23:44:01 CST 2017, time=2017-02-28, status=1, ipAttribution=)]
    2017-03-01 蓬莱阁

    这个可以Meta一下吗?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2069575, encodeId=476f20695e5ef, content=<a href='/topic/show?id=e4063990198' target=_blank style='color:#2F92EE;'>#哌拉西林-他唑巴坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39901, encryptionId=e4063990198, topicName=哌拉西林-他唑巴坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Dec 16 09:28:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544439, encodeId=96181544439e7, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607274, encodeId=4f49160e274d1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178285, encodeId=2d9a1e828537, content=这个可以Meta一下吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Wed Mar 01 06:45:21 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178277, encodeId=17191e8277d5, content=stop, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Wed Mar 01 06:14:05 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178255, encodeId=ff911e825564, content=很好的学习资料,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161026/IMG58107C0F82E499574.jpg, createdBy=00e81970035, createdName=1e15b6fem30(暂无匿称), createdTime=Tue Feb 28 23:44:01 CST 2017, time=2017-02-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2069575, encodeId=476f20695e5ef, content=<a href='/topic/show?id=e4063990198' target=_blank style='color:#2F92EE;'>#哌拉西林-他唑巴坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39901, encryptionId=e4063990198, topicName=哌拉西林-他唑巴坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Dec 16 09:28:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544439, encodeId=96181544439e7, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607274, encodeId=4f49160e274d1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 02 11:28:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178285, encodeId=2d9a1e828537, content=这个可以Meta一下吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Wed Mar 01 06:45:21 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178277, encodeId=17191e8277d5, content=stop, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuF63NQckT5BOaic1el7cRelbpr859YXtZQHQSaWnqZCRPOZzDBcjsBNx7AFefLHh1UvMPS4kPP0BG/0, createdBy=47831990981, createdName=1e1a50a1m36(暂无匿称), createdTime=Wed Mar 01 06:14:05 CST 2017, time=2017-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178255, encodeId=ff911e825564, content=很好的学习资料,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161026/IMG58107C0F82E499574.jpg, createdBy=00e81970035, createdName=1e15b6fem30(暂无匿称), createdTime=Tue Feb 28 23:44:01 CST 2017, time=2017-02-28, status=1, ipAttribution=)]
    2017-02-28 1e15b6fem30(暂无匿称)

    很好的学习资料,谢谢。

    0

相关资讯

哪些抗生素,孕妇不能用?

在临床上,我们经常遇到孕产妇的感染性疾病,需要使用抗生素。很多年轻临床大夫这时候心里就没谱,不知道哪些抗感染药物能用,哪些不能用。

研究发现部分抗生素能“暴力”杀死耐药菌

全球正面临日益严重的细菌耐药性问题。一项发表在英国《科学报告》上的新研究显示,抗生素如果有足够的作用力穿透细菌细胞,就仍可杀死耐药性细菌,这一发现有助未来开发出更有效的抗生素。

儿童阑尾炎:抗生素或可替代手术

急性阑尾炎是儿童急诊进行手术的最常见的原因之一。然而对于国外的年轻家长而言,手术是价格昂贵且会令人担忧的。最近一项最新的对现有文献进行的荟萃分析发现,对于儿童阑尾炎使用抗生素进行治疗可能是一种安全有效的治疗策略。

世卫组织发布迫切需要新型抗生素的细菌清单

世卫组织27日发表了首份抗生素耐药“重点病原体”清单——这是对人类健康构成最大威胁的12种细菌种族目录。

Natur子刊:中国农业大学院士研究组警示抗生素滥用问题

来自中国农业大学的沈建忠教授研究团队对中国的养殖场、屠宰场和超市进行了抽样调查,发现在中国家禽生产流程中普遍存在能让细菌对碳青霉烯和粘菌素产生耐药性的基因。

欧盟细菌抗生素耐药研究取得进展

细菌抗生素耐药已对现实社会构成严重威胁。当听到细菌抗生素耐药时,大部分人会想到“刀枪不入”的超级细菌。实际上细菌通常拥有休眠能力,当遇到外部环境压力时会创建自身毒素(蛋白质)导致细菌休眠,压力解除后创建另一毒素(又称抗毒素)结束休眠状态。药物抗生素一般只对“活着”或正在裂变的细菌产生作用,而对以细菌微生物膜形式出现的休眠细菌无任何作用。欧盟第七研发框架计划为此提供了全额资助进行研究。